---
title: "Moderna doses first patient in Phase 1 trial of mRNA-4200 cancer therapy in solid tumors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292895134.md"
description: "Moderna has dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an off-the-shelf cancer antigen therapy for solid tumors. The study aims to assess the safety and tolerability of mRNA-4200 when administered with checkpoint inhibitor therapy in adults with advanced or metastatic solid tumors. mRNA-4200 encodes seven shared tumor antigens designed to induce and expand T-cell responses across multiple tumor types."
datetime: "2026-07-16T11:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292895134.md)
  - [en](https://longbridge.com/en/news/292895134.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292895134.md)
---

# Moderna doses first patient in Phase 1 trial of mRNA-4200 cancer therapy in solid tumors

-   Moderna dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an off-the-shelf tumor-targeted cancer antigen therapy for solid tumors. \* Study will assess safety and tolerability of mRNA-4200 given with checkpoint inhibitor therapy in adults with advanced or metastatic solid tumors. \* mRNA-4200 encodes seven shared tumor antigens, aiming to induce and expand T-cell responses across multiple tumor types. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607160700ACCESSWRNAPR\_\_\_\_\_1190971) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News](https://longbridge.com/en/news/293731075.md)
- [Moderna (MRNA) Adds Finance Veteran To Its Board, Is The Stock Fully Valued?](https://longbridge.com/en/news/293478959.md)
- [FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development](https://longbridge.com/en/news/293476128.md)
- [Moderna (MRNA) Stock Looks Stretched On Sales But Reasonable On Momentum](https://longbridge.com/en/news/292799347.md)
- [Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?](https://longbridge.com/en/news/291681489.md)